S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
Are blue chip stocks a good investment?
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Power Play: GE's game-changing technology for EVs and grids
Home sales hit a 13-year low... what now?
New CBOE “special perk” helps traders target income every weekend (Ad)
Stock market today: World shares mixed after Wall St ends its best month of '23 with big gains
Salesforce.com completes a reversal: new all-time high in sight
New CBOE “special perk” helps traders target income every weekend (Ad)
A 15% gain in store for Five Below after rosy holiday outlook
Salesforce, Big Lots rise; Pure Storage, Cracker Barrel fall, Thursday, 11/30/2023
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
Are blue chip stocks a good investment?
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Power Play: GE's game-changing technology for EVs and grids
Home sales hit a 13-year low... what now?
New CBOE “special perk” helps traders target income every weekend (Ad)
Stock market today: World shares mixed after Wall St ends its best month of '23 with big gains
Salesforce.com completes a reversal: new all-time high in sight
New CBOE “special perk” helps traders target income every weekend (Ad)
A 15% gain in store for Five Below after rosy holiday outlook
Salesforce, Big Lots rise; Pure Storage, Cracker Barrel fall, Thursday, 11/30/2023
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
Are blue chip stocks a good investment?
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Power Play: GE's game-changing technology for EVs and grids
Home sales hit a 13-year low... what now?
New CBOE “special perk” helps traders target income every weekend (Ad)
Stock market today: World shares mixed after Wall St ends its best month of '23 with big gains
Salesforce.com completes a reversal: new all-time high in sight
New CBOE “special perk” helps traders target income every weekend (Ad)
A 15% gain in store for Five Below after rosy holiday outlook
Salesforce, Big Lots rise; Pure Storage, Cracker Barrel fall, Thursday, 11/30/2023
S&P 500   4,567.80
DOW   35,950.89
QQQ   388.83
Are blue chip stocks a good investment?
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Power Play: GE's game-changing technology for EVs and grids
Home sales hit a 13-year low... what now?
New CBOE “special perk” helps traders target income every weekend (Ad)
Stock market today: World shares mixed after Wall St ends its best month of '23 with big gains
Salesforce.com completes a reversal: new all-time high in sight
New CBOE “special perk” helps traders target income every weekend (Ad)
A 15% gain in store for Five Below after rosy holiday outlook
Salesforce, Big Lots rise; Pure Storage, Cracker Barrel fall, Thursday, 11/30/2023

Catalyst Pharmaceuticals Stock Price, News & Analysis (NASDAQ:CPRX)

$14.43
+0.38 (+2.70%)
(As of 11/30/2023 ET)
Compare
Today's Range
$14.06
$14.51
50-Day Range
$11.69
$14.43
52-Week Range
$11.09
$22.11
Volume
1.18 million shs
Average Volume
1.07 million shs
Market Capitalization
$1.54 billion
P/E Ratio
27.75
Dividend Yield
N/A
Price Target
$24.75

Catalyst Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
71.5% Upside
$24.75 Price Target
Short Interest
Bearish
7.27% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.99
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
42.50%
From $1.60 to $2.28 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.74 out of 5 stars

Medical Sector

70th out of 948 stocks

Pharmaceutical Preparations Industry

23rd out of 448 stocks


CPRX stock logo

About Catalyst Pharmaceuticals Stock (NASDAQ:CPRX)

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

CPRX Stock Price History

CPRX Stock News Headlines

Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Recap: Catalyst Pharmaceuticals Q3 Earnings
Catalyst Pharmaceuticals Inc (CN2.DU)
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Catalyst Pharma Reports FDA Acceptance Of SNDA For FIRDAPSE
See More Headlines
Receive CPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2023
Today
12/01/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/20/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CPRX
Employees
82
Year Founded
2002

Price Target and Rating

Average Stock Price Target
$24.75
High Stock Price Target
$27.00
Low Stock Price Target
$24.00
Potential Upside/Downside
+71.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$83.08 million
Pretax Margin
23.20%

Debt

Sales & Book Value

Annual Sales
$214.20 million
Cash Flow
$0.83 per share
Book Value
$3.27 per share

Miscellaneous

Free Float
93,711,000
Market Cap
$1.54 billion
Optionable
Optionable
Beta
1.08

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report














CPRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Catalyst Pharmaceuticals stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CPRX shares.
View CPRX analyst ratings
or view top-rated stocks.

What is Catalyst Pharmaceuticals' stock price target for 2024?

4 analysts have issued 12-month price objectives for Catalyst Pharmaceuticals' stock. Their CPRX share price targets range from $24.00 to $27.00. On average, they anticipate the company's share price to reach $24.75 in the next twelve months. This suggests a possible upside of 71.5% from the stock's current price.
View analysts price targets for CPRX
or view top-rated stocks among Wall Street analysts.

How have CPRX shares performed in 2023?

Catalyst Pharmaceuticals' stock was trading at $18.60 at the start of the year. Since then, CPRX stock has decreased by 22.4% and is now trading at $14.43.
View the best growth stocks for 2023 here
.

When is Catalyst Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024.
View our CPRX earnings forecast
.

How were Catalyst Pharmaceuticals' earnings last quarter?

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) released its quarterly earnings results on Wednesday, November, 8th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, meeting the consensus estimate of ($0.26). The biopharmaceutical company had revenue of $102.69 million for the quarter, compared to the consensus estimate of $100.17 million. Catalyst Pharmaceuticals had a net margin of 17.81% and a trailing twelve-month return on equity of 19.32%.

What other stocks do shareholders of Catalyst Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD).

Who are Catalyst Pharmaceuticals' major shareholders?

Catalyst Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Northern Trust Corp (1.35%), Jacobs Levy Equity Management Inc. (1.23%), LSV Asset Management (1.16%), Invesco Ltd. (0.96%), Charles Schwab Investment Management Inc. (0.86%) and American Century Companies Inc. (0.84%). Insiders that own company stock include Alicia Grande, Brian Elsbernd, Carmen Jeffrey Del, David S Tierney, Donald A Denkhaus, Gary Ingenito, Patrick J Mcenany, Philip H Coelho, Preethi Sundaram and Steve Miller.
View institutional ownership trends
.

How do I buy shares of Catalyst Pharmaceuticals?

Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CPRX) was last updated on 12/1/2023 by MarketBeat.com Staff

My Account -